Three‐year clinical outcomes after transcatheter aortic valve implantation in patients with bicuspid aortic disease: Comparison between self‐expanding and balloon‐expandable valves
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.31041 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Mauro Boiago und 9 weiteren Autor:innen. Beteiligte Einrichtung: Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Bicuspid Aortic Valve Disease, Heart Valve Prosthesis, Aortic Valve Stenosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Introduction
Bicuspid aortic valve (BAV) stenosis is a complex anatomical scenario for transcatheter aortic valve implantation (TAVI). Favorable short‐term clinical outcomes have been reported with TAVI in this setting, but long‐term data are scarce.
Methods
We retrospectively included, in a single‐center registry, patients with BAV stenosis who underwent TAVI before 2020. We compared patients treated with self‐expanding valves (SEV) versus balloon‐expandable valves (BEV). The primary endpoint was a composite of all‐cause mortality, stroke and need for aortic valve (AV) reintervention at 3 years. Secondary endpoints included each component of the primary endpoint, cardiovascular mortality, permanent pacemaker implantation (PPI) rate, mean gradient and ≥moderate paravalvular leak (PVL) rate.
Results
A total of 150 consecutive patients (SEV = 83, BEV = 67) were included. No significant differences were reported between SEV and BEV groups for the primary composite endpoint (SEV 35.9% vs. BEV 32%, p = 0.66), neither for clinical secondary endpoints (all‐cause mortality SEV 28.1% vs. BEV 28%, p = 0.988; cardiovascular mortality SEV 14.1% vs. BEV 20%, p = 0.399; stroke SEV 12.5% vs. BEV 6%, p = 0.342; need for AV reintervention SEV 0% vs. BEV 0%; PPI SEV 28.1% vs. BEV 24%, p = 0.620). A lower mean gradient persisted up to 3 years in the SEV group (SEV 8.8 ± 3.8 mmHg vs. BEV 10.7 ± 3.2 mmHg, p = 0.063), while no significant difference was found in the rate of ≥ moderate PVL (SEV 3/30 vs. BEV 0/25, p = 0.242).
Conclusions
In this single center registry, we observed favorable 3‐year clinical outcomes in nonselected BAV patients treated with different generation devices, without significant differences between patients receiving SEV or BEV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France.
ORCID-Profile: Mauro Boiago, Chiara De Biase, Alessandro Beneduce, Omar Alessandro Oliva
Zitieren
APA
Boiago, M., Bellamoli, M., De Biase, C., Beneduce, A., Alonso, L. G., Laforgia, P., Feliachi, S., Oliva, O. A., Dumonteil, N., & Tchétché, D. (2024). Three‐year clinical outcomes after transcatheter aortic valve implantation in patients with bicuspid aortic disease: Comparison between self‐expanding and balloon‐expandable valves. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31041
Vancouver
Boiago M, Bellamoli M, De Biase C, Beneduce A, Alonso LG, Laforgia P, et al. Three‐year clinical outcomes after transcatheter aortic valve implantation in patients with bicuspid aortic disease: Comparison between self‐expanding and balloon‐expandable valves. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31041
BibTeX
@article{Boiago2024,
author = {Boiago, Mauro and Bellamoli, Michele and De Biase, Chiara and Beneduce, Alessandro and Alonso, Lola Gutierrez and Laforgia, Pietro and Feliachi, Souehib and Oliva, Omar Alessandro and Dumonteil, Nicolas and Tchétché, Didier},
title = {Three‐year clinical outcomes after transcatheter aortic valve implantation in patients with bicuspid aortic disease: Comparison between self‐expanding and balloon‐expandable valves},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.31041}
}
EUVIMED